ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

ClinicalTrials.gov ID: NCT06649045

Public ClinicalTrials.gov record NCT06649045. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial

Study identification

NCT ID
NCT06649045
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

  • Orforglipron Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 21, 2024
Primary completion
Oct 31, 2026
Completion
Dec 31, 2026
Last update posted
Sep 28, 2025

2024 – 2027

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
Ark Clinical Research Long Beach California 90815
Peninsula Research Associates Rolling Hills Estates California 90274
Artemis Institute for Clinical Research San Diego California 92103
Care Access - Aurora Aurora Colorado 80012
EBGS Clinical Research Center Snellville Georgia 30078
Elite Clinical Trials Blackfoot Idaho 83221
Care Access - Shreveport Shreveport Louisiana 71105
The Sleep Spot - Maimonides Albuquerque New Mexico 87107
Accellacare - Wilmington Wilmington North Carolina 28401
CTI Clinical Research Center Cincinnati Ohio 45212
Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18) Pittsburgh Pennsylvania 15236
Preferred Primary Care Physicians Uniontown Pennsylvania 15401
FutureSearch Trials of Neurology Austin Texas 78731
Prime Revival Research Institute, LLC Flower Mound Texas 75028
Northwest Clinical Research Center Bellevue Washington 98007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06649045, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 28, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06649045 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →